Journal
ANNALS OF NEUROLOGY
Volume 90, Issue 6, Pages 976-982Publisher
WILEY
DOI: 10.1002/ana.26226
Keywords
-
Categories
Funding
- Swiss National Science Foundation [31003A_169664]
- German Research Foundation [TR-128]
- Projekt DEAL
- Swiss National Science Foundation (SNF) [31003A_169664] Funding Source: Swiss National Science Foundation (SNF)
Ask authors/readers for more resources
MOG-antibody associated diseases account for a significant portion of patients with acquired demyelinating disorders, with elevated systemic complement activation observed in both adult and pediatric cases across all clinical syndromes. Complement inhibition should be considered for therapeutic merit in patients with MOGAD.
Myelin oligodendrocyte glycoprotein (MOG)-antibody (Ab)-associated diseases (MOGADs) account for a substantial proportion of pediatric and adult patients who present with acquired demyelinating disorders. Its pathogenesis and optimal therapy are incompletely understood. We profiled systemic complement activation in adult and pediatric patients with MOGAD compared with patients with relapse-onset multiple sclerosis, patients with neuromyelitis optica spectrum disorder, and pediatric control and adult healthy donors. Proteins indicative of systemic classical and alternative complement activation were substantially increased in patients with MOGAD compared to control groups. Elevated levels were detected in both adult and pediatric cases and across all clinical syndromes. Complement inhibition should be explored for its therapeutic merit in patients with MOGAD. ANN NEUROL 2021
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available